Loading Eris Lifesciences…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 869 | 752 | 801 | 790 | 772 |
| Operating profit | 224 | 204 | 211 | 219 | 206 |
| Operating margin | 25.8% | 27.1% | 26.4% | 27.7% | 26.7% |
| Net profit | 142 | 282 | 100 | 120 | 118 |
| Net margin | 16.4% | 37.4% | 12.5% | 15.2% | 15.3% |
| EPS (₹) | 10.26 | 20.57 | 7.32 | 8.81 | 8.64 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 3,115 | 2,879 | 1,991 | 1,662 |
| Operating profit | 841 | 703 | 495 | 422 |
| Operating margin | 27.0% | 24.4% | 24.9% | 25.4% |
| Net profit | 620 | 352 | 392 | 382 |
| Net margin | 19.9% | 12.2% | 19.7% | 23.0% |
| EPS (₹) | 45.26 | 25.81 | 28.79 | 28.07 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 7,366 | 7,036 | 7,040 | 3,667 |
| Total liabilities | 3,470 | 3,765 | 3,818 | 1,447 |
| Shareholders’ equity | 3,903 | 2,854 | 2,586 | 2,196 |
| Total debt | 2,359 | 2,478 | 2,781 | 877 |
| Cash & equivalents | 55 | 200 | 94 | 56 |
| Debt / equity | 0.60 | 0.87 | 1.08 | 0.40 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 538 | 1,065 | 486 | 292 |
| Capital expenditure | -297 | -155 | -129 | -841 |
| Free cash flow | 241 | 910 | 357 | -550 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 15.9% | 12.3% | 15.2% | 17.4% |
| Return on assets | 8.4% | 5.0% | 5.6% | 10.4% |
| Net margin | 19.9% | 12.2% | 19.7% | 23.0% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for ERIS. Finnhub coverage is limited for some India-listed stocks.